Professor Yong-Jie Lu

MBBS, MD, PhD
Professor of Molecular Oncology
Group Leader
Research Focus

We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.

Key Publications

Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol (2020) 203(1):73-82. PMID: 31389764

The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267

DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662

Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904

Major Funding
  • 2021-2026 - Prostate Cancer UK, 'Circulating tumour cells as biomarkers for treatment stratification of localised prostate cancer,' £749,527 (leading Co-PI)
  • 2017-2022- Angle Europe PLC, "The prognostic value of circulating megakaryocytes for cancer patients" £278,000
  • 2020-2022- Orchid, "The Robert Lane Tissue Bank incorporating the Circulating Tumour Cell project" £283,547.46. (Co-PI)
Other Activities
  • Senior Editor: American Journal of Cancer Research
  • Member of prostate cancer ICGC consortium
  • Member of PRACTICAL prostate cancer predisposition study international consortium. 
Research

I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce mortality and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.

Our past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.

There are currently two main research areas of interest:

  • Biomarker discovery and clinical applications, focusing on circulating biomarkers (CTCs, exosomes and other cancer associated circulating cells) for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
  • Mechanisms of prostate cancer metastasis and therapeutic resistance.
Other Activities
  • Senior Editor: American Journal of Cancer Research
  • Editorial Board Member: The Open Breast Cancer Journal
  • Editorial Board Member: Journal of Cancer Research Updates
  • Scientific assessment committee member: France national cancer research programme Canceropole (2007-2014)
  • Research grant reviewer for funding bodies, such as British Medical Research Council (MRC), British National Institute for Health Research (NIHR), UK Prostate Action, Prostate Cancer Research Charity, National Cancer Institute of France, International Association of Cancer Research, Hong Kong Research Grants Council
  • Referee of scientific journals such as Oncogene, J Path, Gene Chromosome Cancer, Br J Cancer, International J Cancer, Carcinogenesis, PloS One, BMC Cancer, Histopathology, Clinical Cancer Research and America Journal of Pathology
  • Member of prostate cancer ICGC consortium
    Member of PRACTICAL prostate cancer predisposition study international consortium
  • Active Member of American Association for Cancer Research
  • Honorable Professor, Second Military Medical University, Shanghai, China
  • Honorable Professor, Naning Medical University, China
  • Visiting Professor, Zhengzhou University Medical College, China
Major Funding
  • 2021-2026 - Prostate Cancer UK, 'Circulating tumour cells as biomarkers for treatment stratification of localised prostate cancer,' £749,527 (leading Co-PI)
  • 2019-2021- CRUK Cancer Early Detection Primer award, 'Exploring platelet miRNA as a novel cost-effective non-invasive liquid biopsy approach to improve prostate cancer diagnosis,' £97,242
  • 2017-2022- Angle Europe PLC, "The prognostic value of circulating megakaryocytes for cancer patients" £278,000
  • 2020-2022- Orchid, "The Robert Lane Tissue Bank incorporating the Circulating Tumour Cell project" £283,547.46. (Co-PI)
  • 2008-2011- Medical Research Council, Associated genes in prostate cancer, £303,225

Recent Publications

AtlFast3: The Next Generation of Fast Simulation in ATLAS Aad G, Abbott B, Abbott DC et al. Computing and Software for Big Science (2022) 6(7)

Emulating the impact of additional proton–proton interactions in the ATLAS simulation by presampling sets of inelastic Monte Carlo events Aad G, Abbott B, Abbott DC et al. Computing and Software for Big Science (2022) 6(7)

Measurement of the energy response of the ATLAS calorimeter to charged pions from W±→τ±(→π±ντ)ντ events in Run 2 data Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(10) 223

The ATLAS inner detector trigger performance in pp collisions at 13 TeV during LHC Run 2 Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(10) 206

Search for Higgs bosons decaying into new spin-0 or spin-1 particles in four-lepton final states with the ATLAS detector with 139 fb−1 of pp collision data at s = 13 TeV Aad G, Abbott B, Abbott DC et al. Journal of High Energy Physics (2022) 2022(10) 41

Observation of electroweak production of two jets in association with an isolated photon and missing transverse momentum, and search for a Higgs boson decaying into invisible particles at 13 TeV with the ATLAS detector Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(10) 105

Performance of the ATLAS Level-1 topological trigger in Run 2 Aad G, Abbott B, Abbott DC et al. European Physical Journal C: Particles and Fields (2022) 82(1)

Measurement of the c-jet mistagging efficiency in tt¯ events using pp collision data at √s=13 TeV collected with the ATLAS detector Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(7)

Search for exotic decays of the Higgs boson into b b¯ and missing transverse momentum in pp collisions at √s = 13 TeV with the ATLAS detector Aad G, Abbott B, Abbott DC et al. Journal of High Energy Physics (2022) 2022(7)

Erratum to: Measurement of hadronic event shapes in high-pT multijet final states at s = 13 TeV with the ATLAS detector Aad G, Abbott B, Abbott DC et al. Journal of High Energy Physics (2021) 2021(10) 53

For additional publications, please click here
Team

Postdoctoral Researchers

  • Rachel Lawrence

PhD Students

  • Caitlin Davis
  • Xueke Wang
  • Junjie Chai
  • Edwina Burke

Clinical Research Fellows

  • Tarek Al-Hammouri

Research Technician

  • Edwina Burke
Biography

Education

  • 1992-1995: Ph.D. student in Chinese Academy of Medical Sciences (CAMS) &  Peking Union Medical College (PUMC), Beijing. (Pathophysiology)
  • 1989-1992: Post-graduate student in Dept. of Biology, Harbin Medical University. (M.D. Medical Genetics.)
  • 1984-1989: Undergraduate medical student in Faculty of Medicine, Henan Medical University.

Appointments

  • Oct 2017-present: Professor of Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
  • July 2010-Sept 2017: Reader (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, Queen Mary University of London (QMUL)
  • Jun 2003-July 2010: Senior Lecturer (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, QMUL.
  • Oct 2001-Jun 2003: Research Associate (deputy Team Leader), Molecular Cytogenetics Laboratory, The Institute of Cancer Research (ICR), Sutton, UK.
  • Apr 2000-Oct. 2001: Senior postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Paediatrics (joint with Section of Molecular Carcinogenesis), ICR, Sutton, UK.
  • Apr 1997-Apr 2000: Postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Cell Biology & Experimental Pathology, ICR, Sutton, UK.
  • Oct 1995-Jan 1997: Visiting Scholar, Molecular Cytogenetics Laboratory, ICR, Sutton, UK.
© 2013 ~ 2022 Cancer Research UK Barts Centre